Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the company's issued share capital as of January 31, 2010:
- Total Issued Shares: 5,665,502,017 Ordinary shares of 25p each.
- Treasury Shares: 474,194,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,191,307,859.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of voting rights for shareholder disclosure calculations.
Investor Verification Checklist
- Verify the total number of voting rights (5,191,307,859) for compliance with Financial Services Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (474,194,158) to calculate the free float accurately.
- Review the company's Form 20-F for comprehensive financial performance data not included in this 6-K.